0000000000247670

AUTHOR

Mustapha Sebbane

showing 2 related works from this author

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A …

2019

Objectives: Copeptin and high-sensitivity cardiac troponin (HS-cTn) assays improve the early detection of non-ST-segment elevation myocardial infarction (NSTEMI). Their sensitivities may, however, be reduced in very early presenters.Setting: We performed a post hoc analysis of three prospective studies that included patients who presented to the emergency department for chest pain onset (CPO) of less than 6 hours.Participants: 449 patients were included, in whom 12% had NSTEMI. CPO occurred 4 hours in 146 patients. The prevalence of NSTEMI was similar in all groups (9%, 13% and 12%, respectively, p=0.281).Measures: Diagnostic performances of HS-cTn and copeptin at presentation were examined…

MaleTime Factors030204 cardiovascular system & hematologyChest pain0302 clinical medicinehigh sensitive cardiac troponinTroponin IMedicine1506Prospective Studies030212 general & internal medicineMyocardial infarctionNon-ST Elevated Myocardial InfarctionProspective cohort studynon st-elevation acute myocardial infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTroponin TRGlycopeptidesGeneral MedicineMiddle Aged3. Good healthchest pain onsetEmergency MedicineCardiologyMedicineFemalevery early presentersmedicine.symptomEmergency Service HospitalAdultmedicine.medical_specialtychest pain03 medical and health sciencesCopeptinPredictive Value of TestsInternal medicinePost-hoc analysisHumansAgedbusiness.industryResearchTroponin IcopeptinEmergency departmentmedicine.disease1691businessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct